Trials / Completed
CompletedNCT00491634
Treosulfan-based Conditioning for Transplantation in AML/MDS
Phase II Trial of Fludarabine Combined With Intravenous Treosulfan and Allogeneic Hematopoietic Stem-cell Transplantation in Patients With Chemo-refractory or Previously Untreated Acute Myeloid Leukemia and Myelodysplastic Syndrome.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Dr. Avichai Shimoni MD · Other Government
- Sex
- All
- Age
- 18 Years – 68 Years
- Healthy volunteers
- Not accepted
Summary
The study hypotheses is that the introduction of dose escalated treosulfan, in substitution to busulfan, will reduce toxicity after allogeneic transplantation while improving myeloablation and and disease control in patients with AML and MDS not eligible for standard transplantation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | treosulfan | 12 g/m2 x 3 days |
| DRUG | Treosulfan | 12 g/m2 x 3 |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2014-06-01
- Completion
- 2014-06-01
- First posted
- 2007-06-26
- Last updated
- 2015-12-02
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT00491634. Inclusion in this directory is not an endorsement.